Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Conversion Efficiency
Contineum Therapeutics, Inc. Class A Common Stock cash flow conversion efficiency. Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.048x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.50 Million) by net assets ($239.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CTNM live share price for real-time trading data and today's change.
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Conversion Ratio Explained
Contineum Therapeutics, Inc. Class A Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency. Also see Contineum Therapeutics, Inc. Class A Com stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALTYNGOLD PLC LS -10
F:FPP0
|
N/A |
|
Xiamen Goldenhome Co Ltd
SHG:603180
|
-0.078x |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
0.149x |
|
Sanghvi Movers Limited
NSE:SANGHVIMOV
|
0.097x |
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
-0.239x |
|
Guangdong New Grand Long Packing Co Ltd
SHE:002836
|
-0.084x |
|
Shenzhen Maxonic Auto Control
SHE:300112
|
0.016x |
|
DWS Municipal Income Trust
NYSE:KTF
|
0.021x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. Review Contineum Therapeutics, Inc. Class A Com (CTNM) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $260.99 Million | $-55.31 Million | -0.212x | -27.80% |
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more